Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAYBREAK study of LY3314814 in mild Alzheimer's disease dementia
2015-005625-39Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lanabecestat in Alzheimer's disease (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-13) score. Started Apr 2016; status: terminated.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2015-005625-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005625-39.